Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2023 4
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
Ngai H, Barragan GA, Tian G, Balzeau JC, Zhang C, Courtney AN, Guo L, Xu X, Wood MS, Drabek JM, Demberg T, Sands CM, Chauvin-Fleurence CN, Di Pierro EJ, Rosen JM, Metelitsa LS. Ngai H, et al. Among authors: di pierro ej. Cancer Immunol Res. 2023 Feb 3;11(2):171-183. doi: 10.1158/2326-6066.CIR-22-0333. Cancer Immunol Res. 2023. PMID: 36484736 Free PMC article.
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: di pierro ej. Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188782 Clinical Trial.
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: di pierro ej. Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046868 Clinical Trial.
Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001-2020.
Arnett A, Siegel DA, Dai S, Thompson TD, Foster J, di Pierro EJ, Momin B, Lupo PJ, Heczey A. Arnett A, et al. Among authors: di pierro ej. medRxiv [Preprint]. 2024 Apr 5:2024.03.25.24304564. doi: 10.1101/2024.03.25.24304564. medRxiv. 2024. Update in: Cancer Epidemiol. 2024 Oct;92:102610. doi: 10.1016/j.canep.2024.102610. PMID: 38633779 Free PMC article. Updated. Preprint.
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: di pierro ej. Nat Med. 2024 Apr;30(4):1210. doi: 10.1038/s41591-024-02799-w. Nat Med. 2024. PMID: 38195754 No abstract available.
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.
Tian G, Courtney AN, Yu H, Bhar S, Xu X, Barragán GA, Martinez Amador C, Ghatwai N, Wood MS, Schady D, Montalbano A, Reddy S, Roche AM, de la Cerda D, Parsons DW, Di Pierro EJ, Bushman FD, Heczey A, Metelitsa LS. Tian G, et al. Among authors: di pierro ej. J Immunother Cancer. 2025 Jan 11;13(1):e010156. doi: 10.1136/jitc-2024-010156. J Immunother Cancer. 2025. PMID: 39800376 Free PMC article.
12 results